Abstract:As a neurobiological process, addiction involves pathological patterns of engagement with substances and a range of behaviors with a chronic and relapsing course. Neuroimaging technologies assess brain activity, structure, physiology, and metabolism at scales ranging from neurotransmitter receptors to large-scale brain networks, providing unique windows into the core neural processes implicated in substance use disorders. Identified aberrations in the neural substrates of reward and salience processing, response inhibition, interoception, and executive functions with neuroimaging can inform the development of pharmacological, neuromodulatory, and psychotherapeutic interventions to modulate the disordered neurobiology. Based on our systematic search, 409 protocols registered on ClinicalTrials.gov include the use of one or more neuroimaging paradigms as an outcome measure in addiction, with the majority (N=268) employing functional magnetic resonance imaging (fMRI), followed by positron emission tomography (PET) (N=71), electroencephalography (EEG) (N=50), structural magnetic resonance imaging (MRI) (N=35) and magnetic resonance spectroscopy (MRS) (N=35). Furthermore, in a PubMed systematic review, we identified 61 meta-analyses including 30 fMRI, 22 structural MRI, 8 EEG, 7 PET, and 3 MRS meta-analyses suggesting potential biomarkers in addictions. These studies can facilitate the development of a range of biomarkers that may prove useful in the arsenal of addiction treatments in the coming years. There is evidence that these markers of large-scale brain structure and activity may indicate vulnerability or separate disease subtypes, predict response to treatment, or provide objective measures of treatment response or recovery. Neuroimaging biomarkers can also suggest novel targets for interventions. Closed or open loop interventions can integrate these biomarkers with neuromodulation in real-time or offline to personalize stimulation parameters and deliver the precise intervention. This review provides an overview of neuroimaging modalities in addiction, potential neuroimaging biomarkers, and their physiologic and clinical relevance. Future directions and challenges in bringing these putative biomarkers from the bench to the bedside are also discussed.

How omics is revealing new roles for glia in addiction

Shared and Divergent Transcriptomic Regulation in Nucleus Accumbens D1 and D2 Medium Spiny Neurons by Cocaine and Morphine

Substance Use and Addiction

Microglia in neuroimmunopharmacology and drug addiction

Gial cells and drug addiction

Glucocorticoid Receptor-Regulated Enhancers Play a Central Role in the Gene Regulatory Networks Underlying Drug Addiction

An emerging multi-omic understanding of the genetics of opioid addiction

Neuroproteomics and its applications in research on nicotine and other drugs of abuse.

Multi-omic network analysis identifies dysregulated neurobiological pathways in opioid addiction

Role of Glial Cells in Neuronal Function, Mood Disorders, and Drug Addiction

Research Progress on the Omics of Methamphetamine Toxic Damage and Addiction

Astrocyte-Neuron Interactions in Substance Use Disorders

Elucidating the molecular symphony: unweaving the transcriptional & epigenetic pathways underlying neuroplasticity in opioid dependence and withdrawal

Pathways from Epigenomics and Glycobiology Towards Novel Biomarkers of Addiction and Its Radical Cure.

The ins and outs of the striatum: Role in drug addiction

Integrative genomics approach identifies glial transcriptomic dysregulation and risk in the cortex of individuals with Alcohol Use Disorder

Neuroscience of Drugs and Addiction

Single-cell whole-brain imaging and network analysis provide evidence of the three-stage hypothesis of addiction

Glial 'omics in ischemia: Acute stroke and chronic cerebral small vessel disease

MicroRNAs in addiction: adaptation's middlemen?

Neuroimaging Biomarkers in Addiction